Shandong Buchang Pharmaceuticals Statistics
Total Valuation
Shandong Buchang Pharmaceuticals has a market cap or net worth of CNY 18.12 billion. The enterprise value is 20.38 billion.
Market Cap | 18.12B |
Enterprise Value | 20.38B |
Important Dates
The last earnings date was Monday, October 28, 2024.
Earnings Date | Oct 28, 2024 |
Ex-Dividend Date | Aug 20, 2024 |
Share Statistics
Shandong Buchang Pharmaceuticals has 1.07 billion shares outstanding. The number of shares has decreased by -1.09% in one year.
Current Share Class | n/a |
Shares Outstanding | 1.07B |
Shares Change (YoY) | -1.09% |
Shares Change (QoQ) | -1.38% |
Owned by Insiders (%) | 58.38% |
Owned by Institutions (%) | 5.16% |
Float | 416.21M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.58 |
PB Ratio | 1.62 |
P/TBV Ratio | n/a |
P/FCF Ratio | 30.98 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.54, with an EV/FCF ratio of 34.85.
EV / Earnings | -69.48 |
EV / Sales | 1.73 |
EV / EBITDA | 21.54 |
EV / EBIT | 35.64 |
EV / FCF | 34.85 |
Financial Position
The company has a current ratio of 1.24, with a Debt / Equity ratio of 0.36.
Current Ratio | 1.24 |
Quick Ratio | 0.46 |
Debt / Equity | 0.36 |
Debt / EBITDA | 4.15 |
Debt / FCF | 6.72 |
Interest Coverage | 4.77 |
Financial Efficiency
Return on equity (ROE) is -4.04% and return on invested capital (ROIC) is 2.37%.
Return on Equity (ROE) | -4.04% |
Return on Assets (ROA) | 1.75% |
Return on Capital (ROIC) | 2.37% |
Revenue Per Employee | 1.42M |
Profits Per Employee | -35,291 |
Employee Count | 8,311 |
Asset Turnover | 0.58 |
Inventory Turnover | 1.06 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.06% in the last 52 weeks. The beta is 0.52, so Shandong Buchang Pharmaceuticals's price volatility has been lower than the market average.
Beta (5Y) | 0.52 |
52-Week Price Change | -5.06% |
50-Day Moving Average | 16.49 |
200-Day Moving Average | 16.12 |
Relative Strength Index (RSI) | 50.74 |
Average Volume (20 Days) | 7,250,490 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shandong Buchang Pharmaceuticals had revenue of CNY 11.78 billion and -293.31 million in losses. Loss per share was -0.27.
Revenue | 11.78B |
Gross Profit | 6.93B |
Operating Income | 571.87M |
Pretax Income | -184.40M |
Net Income | -293.31M |
EBITDA | 930.24M |
EBIT | 571.87M |
Loss Per Share | -0.27 |
Balance Sheet
The company has 1.31 billion in cash and 3.93 billion in debt, giving a net cash position of -2.62 billion or -2.46 per share.
Cash & Cash Equivalents | 1.31B |
Total Debt | 3.93B |
Net Cash | -2.62B |
Net Cash Per Share | -2.46 |
Equity (Book Value) | 10.80B |
Book Value Per Share | 10.47 |
Working Capital | 1.47B |
Cash Flow
In the last 12 months, operating cash flow was 917.66 million and capital expenditures -332.84 million, giving a free cash flow of 584.82 million.
Operating Cash Flow | 917.66M |
Capital Expenditures | -332.84M |
Free Cash Flow | 584.82M |
FCF Per Share | 0.55 |
Margins
Gross margin is 58.88%, with operating and profit margins of 4.86% and -2.49%.
Gross Margin | 58.88% |
Operating Margin | 4.86% |
Pretax Margin | -1.57% |
Profit Margin | -2.49% |
EBITDA Margin | 7.90% |
EBIT Margin | 4.86% |
FCF Margin | 4.97% |
Dividends & Yields
This stock pays an annual dividend of 0.13, which amounts to a dividend yield of 0.74%.
Dividend Per Share | 0.13 |
Dividend Yield | 0.74% |
Dividend Growth (YoY) | -86.88% |
Years of Dividend Growth | 1 |
Payout Ratio | n/a |
Buyback Yield | 1.09% |
Shareholder Yield | 1.83% |
Earnings Yield | -1.58% |
FCF Yield | 3.23% |
Stock Splits
The last stock split was on August 19, 2019. It was a forward split with a ratio of 1.3.
Last Split Date | Aug 19, 2019 |
Split Type | Forward |
Split Ratio | 1.3 |
Scores
Shandong Buchang Pharmaceuticals has an Altman Z-Score of 2.49. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.49 |
Piotroski F-Score | n/a |